Hanjing Xie

Hanjing Xie has extensive work experience in the field of oncology and hematology. They have held various senior positions in leading pharmaceutical and healthcare organizations. Starting in 1993, Xie worked as a Consultant in Hematology and Internal Medicine at Hebei Medical University Hospital until 1999. They then joined Karolinska Universitetssjukhuset as a Senior Consultant in Clinical Oncology and Hematology, where they worked until 2016.

In 2015, Xie joined Bayer as a Senior Medical Advisor for Scandinavia, specializing in Oncology and Hematology. They remained in this role until 2018.

From 2016 to 2020, Xie worked at Capio Sverige, initially as a Senior Consultant in Clinical Oncology and later as the Head of the Cancer Clinical Trials Unit.

Xie joined Oncopeptides AB in 2020, first as a Global Clinical Study Physician and then as a Senior Medical Study Director. They held these positions until 2022.

In 2022, Xie joined Idogen AB as their Chief Medical Officer, and in 2023, they held the same position at Kancera. Currently, Xie is also the Chief Medical Officer at NEOGAP Therapeutics AB.

Hanjing Xie's education history is as follows:

Hanjing Xie obtained an MD (Doctor of Medicine) degree from Hebei Medical University in 1993. Later, they pursued a PhD in Clinical Pharmacology at Karolinska Institutet and successfully completed it in 2004. Xie then went on to earn an MD degree with svenska legitimation (Swedish medical license) at Karolinska Institutet in 2005. They currently hold the position of Associate Professor (Docent) in Oncology at Karolinska Institutet. In the future, Xie is planning to participate in the European Innovation Council Women Leadership Programme, which they are expected to start in 2023.